Using proteolysis-targeting chimera technology to reduce navitoclax platelet toxicity and improve its senolytic activity. Nat Commun. 2020 Apr 24;11(1):1996. PMID:32332723 DOI:10.1038/s41467-020-15838-0
Target: BCL2L1 Bcl-2-like protein 1 Q07817 Homo sapiens
E3 ligase: Cereblon
E3 binder: Pomalidomide
SMILES: show
Nc1cccc2c1C(=O)N(C1CCC(=O)NC1=O)C2=O

Ligand Name: ABT-263
Ligand PDB Id: 1XJ
PDB with Ligand: 6QGH
SMILES: show
C1(=CC=C(C=C1)C2=C(CC(CC2)(C)C)CN3CCN(CC3)C4=CC=C(C=C4)C(=O)N[S](C5=CC=C(C(=C5)[S](C(F)(F)F)(=O)=O)NC(CCN6CCNCC6)CSC7=CC=CC=C7)(=O)=O)Cl

Calculated Values
MW: 1,484.16
Hbond donors: 4
Hbond acceptors: 21
cLogP: 8.76
TPSA: 284.19

SMILES: show
CC%11(C)CC/C(c1ccc(Cl)cc1)=C(CN%10CCN(c9ccc(C(=O)NS(=O)(=O)c8ccc(NC(CCN6CCN(C(=O)CCCn5cc(COCCOCCNc3cccc4c(=O)n(C2CCC(=O)NC2=O)c(=O)c34)nn5)CC6)CSc7ccccc7)c(S(=O)(=O)C(F)(F)F)c8)cc9)CC%10)\C%11

Linker type: Other
Incubation time (hours): 16
Cells: WI38 platelets
DC50: = 46 nM
Dmax: = 96.2 %
Tested a non-binding E3 control?: Yes
Tested competition with ligand?: Yes
Tested proteaseome inhibitor?: Yes
Proteomics data available?: No
Tested engagement in cells?: No
Contributed by: Barr Tivon